vs
Side-by-side financial comparison of Amarin Corp plc (AMRN) and Avidbank Holdings, Inc. (AVBH). Click either name above to swap in a different company.
Amarin Corp plc is the larger business by last-quarter revenue ($45.1M vs $28.0M, roughly 1.6× Avidbank Holdings, Inc.). Avidbank Holdings, Inc. runs the higher net margin — 32.3% vs -23.3%, a 55.5% gap on every dollar of revenue.
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
Avidbank Holdings, Inc. is a U.S.-based financial holding company operating through its subsidiary AvidBank. It offers commercial banking products and services primarily to small and medium-sized enterprises, business owners, and high-net-worth individuals across California, including commercial loans, deposit accounts, cash management, and customized financing solutions for sectors like manufacturing, technology, real estate and professional services.
AMRN vs AVBH — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $45.1M | $28.0M |
| Net Profit | $-10.5M | $9.0M |
| Gross Margin | — | — |
| Operating Margin | 35.5% | — |
| Net Margin | -23.3% | 32.3% |
| Revenue YoY | 7.0% | — |
| Net Profit YoY | 33.0% | 65.9% |
| EPS (diluted) | — | $0.84 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $45.1M | $28.0M | ||
| Q4 25 | $49.2M | $26.8M | ||
| Q3 25 | $49.7M | $48.0K | ||
| Q2 25 | $72.7M | $21.8M | ||
| Q1 25 | $42.0M | — | ||
| Q4 24 | $62.3M | — | ||
| Q3 24 | $42.3M | — | ||
| Q2 24 | $67.5M | — |
| Q1 26 | $-10.5M | $9.0M | ||
| Q4 25 | $-1.2M | $6.9M | ||
| Q3 25 | $-7.7M | $-37.7M | ||
| Q2 25 | $-14.1M | $5.8M | ||
| Q1 25 | $-15.7M | — | ||
| Q4 24 | $-48.6M | — | ||
| Q3 24 | $-25.1M | — | ||
| Q2 24 | $1.5M | — |
| Q1 26 | — | — | ||
| Q4 25 | 47.1% | — | ||
| Q3 25 | 44.7% | — | ||
| Q2 25 | 69.2% | — | ||
| Q1 25 | 59.8% | — | ||
| Q4 24 | -15.4% | — | ||
| Q3 24 | 38.5% | — | ||
| Q2 24 | 63.4% | — |
| Q1 26 | 35.5% | — | ||
| Q4 25 | -12.9% | — | ||
| Q3 25 | -22.4% | -110491.7% | ||
| Q2 25 | -22.0% | 38.0% | ||
| Q1 25 | -39.9% | — | ||
| Q4 24 | -84.3% | — | ||
| Q3 24 | -59.5% | — | ||
| Q2 24 | -0.8% | — |
| Q1 26 | -23.3% | 32.3% | ||
| Q4 25 | -2.5% | 25.9% | ||
| Q3 25 | -15.6% | -78614.6% | ||
| Q2 25 | -19.4% | 26.6% | ||
| Q1 25 | -37.4% | — | ||
| Q4 24 | -78.0% | — | ||
| Q3 24 | -59.4% | — | ||
| Q2 24 | 2.3% | — |
| Q1 26 | — | $0.84 | ||
| Q4 25 | $0.00 | $0.65 | ||
| Q3 25 | $-0.02 | $-4.12 | ||
| Q2 25 | $-0.03 | $0.75 | ||
| Q1 25 | $-0.04 | — | ||
| Q4 24 | $-0.12 | — | ||
| Q3 24 | $-0.06 | — | ||
| Q2 24 | $0.00 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $307.8M | — |
| Total DebtLower is stronger | — | $55.0M |
| Stockholders' EquityBook value | — | $287.2M |
| Total Assets | $645.8M | $2.5B |
| Debt / EquityLower = less leverage | — | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $307.8M | — | ||
| Q4 25 | $302.6M | — | ||
| Q3 25 | $286.6M | — | ||
| Q2 25 | $298.7M | — | ||
| Q1 25 | $281.8M | — | ||
| Q4 24 | $294.2M | — | ||
| Q3 24 | $305.7M | — | ||
| Q2 24 | $306.7M | — |
| Q1 26 | — | $55.0M | ||
| Q4 25 | — | $60.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $287.2M | ||
| Q4 25 | $459.3M | $278.4M | ||
| Q3 25 | $458.9M | $273.1M | ||
| Q2 25 | $464.9M | $204.4M | ||
| Q1 25 | $473.7M | — | ||
| Q4 24 | $486.2M | — | ||
| Q3 24 | $531.4M | — | ||
| Q2 24 | $551.9M | — |
| Q1 26 | $645.8M | $2.5B | ||
| Q4 25 | $670.8M | $2.5B | ||
| Q3 25 | $659.8M | $2.4B | ||
| Q2 25 | $670.1M | $2.4B | ||
| Q1 25 | $655.7M | — | ||
| Q4 24 | $685.3M | — | ||
| Q3 24 | $750.6M | — | ||
| Q2 24 | $799.9M | — |
| Q1 26 | — | 0.19× | ||
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
AVBH
| Net Interest Income | $26.5M | 95% |
| Noninterest Income | $1.5M | 5% |
